Clinical Trial Data of Anti –PD-1/PD-L1 Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Review

Nasopharyngeal carcinoma (NPC) is a distinct type of head and neck cancer that differs from other head and neck cancers in terms of etiology and treatment [1,2]. In fact, clinical trials leading to the approval of pembrolizumab (KEYNOTE-048) and nivolumab (CheckMate 141) for the treatment of squamous cell carcinoma of the head and neck specifically excluded patients with NPC [1]. NPC is commonly classified by its major histological subtypes (keratinizing squamous cell carcinoma, nonkeratinizing differentiated cell carcinoma, nonkeratinizing undifferentiated carcinoma, or other) and disease stage [2,3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research